+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Contrast Media Injectors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029

  • PDF Icon


  • 135 Pages
  • February 2024
  • Region: Global
  • Mordor Intelligence
  • ID: 4622537
The Contrast Media Injectors Market size is estimated at USD 1.82 billion in 2024, and is expected to reach USD 2.59 billion by 2029, growing at a CAGR of 7.44% during the forecast period (2024-2029).

The COVID-19 pandemic has had a devastating impact on the global population's health and a significant economic impact on most countries. The volume of imaging cases in many radiology departments dropped dramatically. The COVID-19 outbreak impacted patients' access to healthcare facilities as the pandemic forced them to wait for lifesaving imaging procedures. The pandemic also increased the waiting time for patients to have their imaging done. According to an article published by the Radiology Society of North America in April 2020, the COVID-19 pandemic profoundly impacted radiology practices across the country. The volume of diagnostic imaging and the number of CT and MRI machines installed will primarily determine the demand for contrast injectors. The easing of norms and the start of vaccination programs led to a recovery in the contrast media injectors market.

The major factors attributed to the growth of the contrast media injectors market are increasing demand for minimally invasive surgeries, technological advancements, and increasing regulatory approvals. Several advancements in contrast media injector technology have been made to reduce contrast media waste and automate data collection regarding the dose received by a patient. For example, the automated injector systems precisely collect the amount of contrast media used. Vendors offer personalized doses to patients, using the information pulled from EMR or picture archiving and communication systems (PACS). One such advancement in reducing contrast media waste is syringeless injectors.

According to the WHO updates from July 2021, cardiovascular diseases (CVDs) are the number one cause of death globally. An estimated 17.9 million each year suffer from cardiovascular diseases. Four out of five cardiovascular deaths are due to strokes and heart attacks, and one-third of deaths occur prematurely in people under 70 years. Similarly, according to the WHO 2021 fact sheet, non-communicable diseases (NCDs), also known as chronic diseases, are responsible for the death of about 41 million people each year, which was about 71% of the total deaths recorded all over the world. As per the same source, every year, over 15 million people aged between 30-69 years die due to NCDs across the world. Thus, due to the high burden of mortality due to NCDs, the demand for diagnostic procedures is increasing. As minimally invasive procedures have more advantages over traditional procedures, they are gaining traction, and thereby, the demand for contrast media injectors is expected to increase.

Most companies are developing innovative products to reduce contrast media waste and gain a competitive advantage. Bracco has developed smart syringeless injectors, which can use every drop of contrast loaded into the system for maximum economy. Smart injectors record the amount injected and the imaging protocol used and send the information to the PACS. These constant technological advancements in contrast to media injector technology are expected to boost the market during the forecast period.

However, the high cost of contrast media injectors and adverse effects of contrast agents are expected to plummet the growth of the market over the forecast period.

Contrast Media Injectors Market Trends

The CT Injector Systems Segment is Expected to Record a High CAGR in the Injectors Segment

CT injectors are expected to grow positively as the usage of CT systems has increased over the past few years. These CT systems use a dual-head injector with two syringes for initial and follow-up contrast doses during imaging. There has been constant R&D activity by major academic centers and pharmaceutical companies to develop protocols that help CT users with the advanced capabilities of newer imaging systems.

Major players are gradually implementing various strategies, such as collaborative initiatives, to remain competitive in the market. For example, In May 2022, Bayer Korea said it had started marketing MEDRAD Centargo, a computed tomography (CT) injection medical device, which received approval from the Ministry of Food and Drug Safety in January. Similarly, Ulrich Medical, a German medical technology company, presented a version of its CT motion contrast media injector designed for the American market at the RSNA in Chicago in May 2020. It was approved by the FDA and marketed in collaboration with GE Healthcare.

Such factors are expected to boost the market's growth over the forecast period positively.

North America is Expected to Hold a Significant Share in the Market and Continue the Growth Trend During the Forecast Period

North America is expected to dominate the overall market during the forecast period, primarily due to the increasing preference for minimally invasive procedures and the increasing prevalence of chronic diseases due to changing lifestyles. The United States holds the largest market share in the region.

According to the CDC data updated in May 2021, chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. They also contribute to USD 3.8 trillion in annual healthcare costs. Six in 10 adults in the country have a chronic disease, and four in every 10 have two or more chronic diseases.

Additionally, according to Heart Disease & Stroke Statistical Fact Sheet 2020, a minimum of 40,000 infants are expected to be affected yearly by congenital heart defects in the United States. About 25% or 2.4 (per 1,000 live births) require treatment in the first year of an infant's life.

Technological advancements in contrast media injector devices, increasing expenditure by key players, and rising regulatory approvals are also boosting the growth of the contrast media injectors market in North America.

Contrast Media Injectors Industry Overview

The contrast media injectors market is consolidated, competitive, and consists of a few major players. In terms of market share, few major players currently dominate the market. With increasing technological advancements, the high prevalence of diseases, and the increasing usage of minimally invasive surgeries, more companies are expected to enter the market in the coming years. Major players in the market are Bracco Group, GE Healthcare, Bayer HealthCare, Medtron AG, and Ulrich GmbH & Co. KG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Minimally Invasive Surgeries
4.2.2 Technological Advancements and Increasing Number of Regulatory Approvals
4.3 Market Restraints
4.3.1 High Cost of Contrast Media Injectors
4.3.2 Adverse Effects of Contrast Agents
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Products
5.1.1 Injector Systems CT Injector Systems MRI Injector Systems Cardiovascular/Angiography Injector Systems
5.1.2 Consumables Tubing Syringe Other Consumables
5.2 By Type of Injectors
5.2.1 Single-head Injectors
5.2.2 Dual-head Injectors
5.2.3 Syringeless Injectors
5.3 By Application
5.3.1 Radiology
5.3.2 Interventional Cardiology
5.3.3 Other Applications
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Bracco Group
6.1.2 Guerbet Group
6.1.3 Medtron AG
6.1.4 Bayer HealthCare LLC
6.1.5 ulrich GmbH & Co. KG
6.1.6 Nemoto Kyorindo Co. Ltd
6.1.7 GE Healthcare (GE Company)
6.1.8 Hilin Life Products
6.1.9 Sino Medical-Device Technology Co. Ltd
6.1.10 APOLLO RT Co. Ltd
6.1.11 Shenzen Seacrown Electromechanical Co. Ltd
6.1.12 Shenzhen Anke High-tech Co. Ltd

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bracco Group
  • Guerbet Group
  • Medtron AG
  • Bayer HealthCare LLC
  • ulrich GmbH & Co. KG
  • Nemoto Kyorindo Co. Ltd
  • GE Healthcare (GE Company)
  • Hilin Life Products
  • Sino Medical-Device Technology Co. Ltd
  • APOLLO RT Co. Ltd
  • Shenzen Seacrown Electromechanical Co. Ltd
  • Shenzhen Anke High-tech Co. Ltd